Scarica l'app Stockscreener
330.11
3.37%
-11.53
Dopo l'orario di chiusura:
330.49
0.38
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
Amgen (AMGN) Valuation Check After DISCO Oncology Deal And Fresh Analyst Optimism - simplywall.st
Amgen (NASDAQ:AMGN) Price Target Raised to $319.00 at Truist Financial - MarketBeat
Goldman Sachs Adjusts Price Target on Amgen to $403 From $400, Maintains Buy Rating - MarketScreener
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan - TipRanks
Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors? - Yahoo Finance
Amgen acquires British Dark Blue Therapeutics for USD 840m - medwatch.com
SG Americas Securities LLC Has $79.95 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by HB Wealth Management LLC - MarketBeat
Evotec benefits from Dark Blue acquisition by Amgen - European Biotechnology Magazine
Biotech Amgen acquires UK-based Dark Blue Therapeutics in $840m deal - Silicon Republic
Amgen Inc.: How a Biotech Powerhouse Is Re-Architecting Its Drug Platform for the Next Decade - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by Benjamin Edwards Inc. - MarketBeat
Call for Application for 2026 Tsinghua Amgen Scholars Program - PR Newswire
Humira Market to Witness Remarkable Growth With AbbVie Inc., Amgen Inc., Samsung Bioepis - openPR.com
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - PR Newswire
Amgen Inc.: How a Biotech Veteran Is Re?Engineering Its Own Future - AD HOC NEWS
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs - Benzinga
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial - TipRanks
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline - Finviz
UBS Raises Amgen (AMGN) Price Target to $380 and Upgrades to Buy - GuruFocus
Amgen acquires cancer drugmaker Dark Blue Therapeutics for up to $840 mn - ETPharma.com
Amgen buys Dark Blue Therapeutics in $840m oncology deal - Yahoo Finance
Robeco Institutional Asset Management B.V. Has $123.48 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
UBS assumes coverage on Amgen stock with Buy rating, $380 price target - Investing.com UK
CX Institutional Increases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 - simplywall.st
Cerity Partners LLC Sells 6,837 Shares of Amgen Inc. $AMGN - MarketBeat
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies - GlobeNewswire Inc.
CWA Asset Management Group LLC Sells 14,786 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Acquires Dark Blue Therapeutics In Deal Valued At Up To $840 Million - Pulse 2.0
Amgen Acquires Dark Blue in $840 Million Deal to Pursue Innovative Leukemia Treatments - Bitget
Amgen adds AML candidate in deal for U.K.-based Dark Blue: Deals Report - biocentury.com
UBS Upgrades Amgen (AMGN) to Buy, Raises Price Target to $380 - GuruFocus
Amgen upgraded to buy at UBS on potential of MariTide, olpasiran - Seeking Alpha
Amgen Paints Pipeline Dark Blue In Acquisition of Small Molecule Developer - Citeline News & Insights
Amgen’s Own High Court Loss Cited in Pushback to Evenity Claims - Bloomberg Law News
Amgen Agrees to Buy Dark Blue Therapeutics in Up to $840 Million Deal - GuruFocus
Amgen swoops on UK cancer biotech in deal worth up to $840mn - Financial Times
Amgen buys protein-degrading startup Dark Blue for up to $840M - BioPharma Dive
$840 million Dark Blue buy hands Amgen AML drug - The Pharma Letter
Amgen buys UK biotech Dark Blue Therapeutics for up to $840m - Sharecast.com
Amgen to buy blood cancer biotech Dark Blue Therapeutics in $840M deal - Axios
Amgen acquires Dark Blue Therapeutics, bolstering oncology pipeline - MarketScreener
Amgen adds preclinical cancer asset via $840M deal for Dark Blue Therapeutics - FirstWord Pharma
Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million - MarketScreener
Amgen (AMGN) Acquires Dark Blue Therapeutics for $840 Million - GuruFocus
Amgen acquires Dark Blue Therapeutics for up to $840 million - Investing.com
Dark Blue Therapeutics acquired by Amgen for up to $840 million - MarketScreener
Amgen (AMGN) Expands Oncology Portfolio with Acquisition of Dark Blue Therapeutics - GuruFocus
Amgen acquires Dark Blue Therapeutics for up to $840 million By Investing.com - Investing.com Canada
Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal - Nasdaq
New acute leukemia approach behind Amgen's $840M acquisition - Stock Titan
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE - PR Newswire
Amgen Buys Cancer Drug Developer Dark Blue in $840 Million Deal - Bloomberg.com
Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease - BioSpace
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What to Expect From Amgen's Q4 2025 Earnings Report - Barchart.com
Commonwealth Equity Services LLC Has $105.58 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? - MedCity News
D.A. Davidson & CO. Purchases 6,222 Shares of Amgen Inc. $AMGN - MarketBeat
Greenspring Advisors LLC Makes New $1.69 Million Investment in Amgen Inc. $AMGN - MarketBeat
AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug - BioSpace
Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus - Yahoo Finance
2.96%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):